Sangamo Therapeutics Inc. has reported data from nonhuman primate (NHP) studies showing the potential of its proprietary AAV capsid variant, STAC-BBB, as a neurotropic capsid when administered intravenously at clinically relevant doses. STAC-BBB outperformed results for other evaluated neurotropic capsid variants.